Examining of Health Policy in Rare Diseases in Terms of Historical Perspective in Turkey

Yıl 2021, Cilt: 7 Sayı: 14, 62 - 71, 31.10.2021

Merve Deniz Pak Güre Özgür İnce

https://doi.org/10.48121/jihsam.874683

Cited By: 2

Öz

Compared with other common diseases in the general population, a rare disease is a health condition that affects a small number of people. The progressive, life-threatening and multi-dimensional nature of these diseases requires the development of an effective health policy. The aim of this study is to examine health policy for rare diseases from a historical point of view in Turkey. Public Health Law No. 1593 provides the basis for policies developed in the field of rare diseases. In the early 2000s, genetic screening programs have been launched (neonatal metabolic and endocrine disease, inherited blood diseases, biotinidase deficiency, phenylketonuria, congenital hypothyroidism, adrenal hyperplasia, cystic fibrosis, etc.). Since 2007, Turkey has been a member of Orphanet. The Draft Guide to Orphan Drugs was published by the Ministry of Health in 2009. Since 2014, the public authorities, universities, and NGOs have been particularly interested in rare diseases. The civil society initiative 'Rare Diseases Network' was established in 2018 under the leadership of patients and their families. Some reports on rare diseases were published by TÜHKE and the TAÇESE in 2019. The Parliamentary Investigation Commission has been set up to determine the situation of some rare diseases. The Rare Diseases Department was established within the Ministry of Health in 2020. It is recommended that the National Action Plan on Rare Diseases and Orphan Drugs should be implemented to develop policies, in particular access to healthcare services, and provide economic and psychosocial support.

Anahtar Kelimeler

Rare diseases, Orphan drugs, Health policy, Healthcare services

Kaynakça

• Aba, G. (2018). Sağlık Politikası ve Planlaması. Nobel Yayıncılık.
• Acıbadem Üniversitesi. (2019). İSTisNA-İstanbul Tanısız ve Nadir Hastalıklara Çözüm Platformu Fizibilite Desteği Projesi. https://www.acibadem.edu.tr/haberler/istisna-istanbul-tanisiz-ve-nadir-hastaliklara-cozum-platformu-fizibilite-destegi-projesi
• ACURARE. (nd). Hakkında. https://www.acibadem.edu.tr/rare/hakkinda/merkez-tanimi-ve-kurulus-gerekcesi
• Aksu, B. (2009). Rare Disease and Orphan Drug Situations in Turkey and around the World. Aurum Journal of Health Sciences, 1(2), 95-109.
• Allotey, P. A., Allotey-Reidpath, C. D., & Reidpath, D. D. (2018). Health systems implications of rare genetic conditions in low-and middle-income countries: a case study approach. Critical Public Health, 28(2), 248-252. https://doi.org/10.1080/09581596.2017.1344772
• Anderson, M., Elliott, E. J., & Zurynski, A. Y. (2013). Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. Orphanet Journal of Rare Diseases, 8(22), 1-9. https://doi.org/10.1186/1750-1172-8-22
• Aujoulat, I., Young, B., & Salmon, P. (2012). The psychological processes involved in patient empowerment. Orphanet Journal of Rare Diseases, 7(2), 31. https://doi.org/10.1186/1750-1172-7-S2-A31
• Aymé, S., Kole, A., & Groft, S. (2008). Empowerment of patients: lessons from the rare diseases community. The Lancet, 371(9629), 2048-2051. https://doi.org/10.1016/S0140-6736(08)60875-2
• Aymé, S., & Rodwell, C. (2012). Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases. https://op.europa.eu/en/publication-detail/-/publication/67da4f31-41ff-4b77-a9ca-dfda08582219/language-en
• Bogart, K. R., & Irvin, V. L. (2017). Health-related quality of life among adults with diverse rare disorders. Orphanet journal of rare diseases, 12(1), 177. https://doi.org/10.1186/s13023-017-0730-1
• Buse, K., Mays, N., & Walt, G. (2012). Making health policy. McGraw-hill education (UK). London. Castillo-Esparcia, A., & López-Villafranca, P. (2016). Communication strategies employed by rare disease patient organizations in Spain. Ciência & Saúde Coletiva, 21, 2423-2436. https://doi.org/10.1590/1413-81232015218.19852015
• Czech, M., Baran-Kooiker, A., Atikeler, K., Demirtshyan, M., Gaitova, K., Holownia-Voloskova, M., ... & Sykut-Cegielska, J. (2020). A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries. Frontiers in public health, 7, 416. https://doi.org/10.3389/fpubh.2019.00416
• Choudhury, M. C., & Saberwal, G. (2019). The role of patient organizations in the rare disease ecosystem in India: an interview based study. Orphanet journal of rare diseases, 14(1), 117. https://doi.org/10.1186/s13023-019-1093-6
• Çocuklar için özel gereksinim raporu (ÇÖZGER). (2019). Sayı:30692
• Dharassi, S., Wong-Rieger, D., Harold, M. & Terry, S. (2017). Review of 11 national policies for rare diseases in the context of key patient needs. Orphanet Journal of Rare Diseases, 12 (63). https://doi.org/10.1186/s13023-017-0618-0
• Dündar, M., & Yeșim Karabulut, S. (2010). Rare disease and orphan drugs in Turkey; medical and social problem. Erciyes Medical Journal, 32(3), 195-200.
• EJP – RD. (2020). Call for Proposals 2021. https://www.ejprarediseases.org/wp-content/uploads/2020/12/JTC2021-1-Call-text-VF.pdf
• Erçin, S. & Ovalı, F. (2019). Yenidoğan Taramaları. Klinik Tıp Pediatri Dergisi, 11(4), 193-199.
• EURORDIS. (2009). The voice of 12,000 patients. Experiences and expectations of rare disease patients on diagnosis and Care in Europe: Eurordis; 2009.
• EURORDIS. (2017). What is a rare disease? http://www.eurordis.org/sites/default/files/publications/Fact_Sheet_RD.pdf, Erişim tarihi: 12.12.2020.
• Forman, J., Taruscio, D., Llera, V. A., Barrera, L. A., Coté, T. R., Edfjäll, C., ... & International Conference for Rare Diseases and Orphan Drugs (ICORD). (2012). The need for worldwide policy and action plans for rare diseases. Acta Paediatrica, 101(8), 805-807. https://doi.org/10.1111/j.1651-2227.2012.02705.x
• Gammie, T., Lu, C. Y., & Babar, Z. U. D. (2015). Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PloS one, 10(10), e0140002. https://doi.org/10.1371/journal.pone.0140002
• GARD. (Genetic and Rare Diseases Information Center) (2017). GARD FAQs about rare diseases. https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases
• Haendel, M., Vasilevsky, N., Unni, D., Bologa, C., Harris, N., Rehm, H., ... & Dawkins, H. (2019). How many rare diseases are there?. Nature Reviews Drug Discovery 19, 77-78. https://doi.org/10.1038/d41573-019-00180-y
• Halk Sağlığı Genel Müdürlüğü. (2018). Yenidoğan Metabolik ve Endokrin Hastalık Tarama Programı (NTP). https://hsgm.saglik.gov.tr/tr/cocukergen-tp-liste/yenido%C4%9Fan-i%CC%87%C5%9Fitme-taramas%C4%B1-program%C4%B1.html
• Halk Sağlığı Genel Müdürlüğü (2018). https://hsgm.saglik.gov.tr/tr/cocukergen-tp-liste/yenidogan_tarama_programi.html.
• Huang, R., Wei, Y., Hu, J., Kong, F., He, J., Yang, Y., ... & Kang, Q. (2019). The progress of, challenges faced by, and future of rare disease patient organizations in China. Intractable & Rare Diseases Research, 8(2), 158-160. https://doi.org/10.5582/irdr.2019.01069
• I. Türk Tıp Dünyası Kurultayı. (2014). Kurultay Raporu. https://docplayer.biz.tr/3414174-Turk-tip-dunyasi-kurultayi-29-31-ekim-2014-istanbul.html.
• II. Türk Tıp Dünyası Kurultayı. (2015). Kurultay Raporu. https://disab.saglik.gov.tr/Eklenti/2101/0/2ttdkkitappdf.pdf
• İlaç Bilincini Geliştirme ve Akılcı İlaç Derneği (2014). ‘Nadir Hastalıklar ve Yetim İlaç Sempozyumu ve Yetim İlaç Yönetmelik Çalıştayı’ Raporu. https://www.akilciilacdernegi.com/uploads/kongre/toplanti.pdf
• İstanbul Üniversitesi Deneysel Tıp Araştırma Enstitüsü-İstanbul Tıp Fakültesi-Orphanet. (2016). Türkiye Nadir Hastalıklar Günü Sempozyumu. http://cdn.istanbul.edu.tr/statics/www.istanbul.edu.tr/wp-content/uploads/2016/02/nadir_hastaliklar_gunu_programi_29_subat_2016_SON.pdf
• Kalıtsal Hastalıklarla Mücadele Kanunu. (1993). Kanun no: 3960.
• Khosla, N., & Valdez, R. (2018). A compilation of national plans, policies and government actions for rare diseases in 23 countries. Intractable & Rare Diseases Research, 7(4), 213-222. https://doi.org/10.5582/irdr.2018.01085
• Koay, P. P., & Sharp, R. R. (2013). The role of patient advocacy organizations in shaping genomic science. Annual review of genomics and human genetics, 14, 579-595. https://doi.org/10.1146/annurev-genom-091212-153525
• Linertová, R., García-Pérez, L., & Gorostiza, I. (2017). Cost-of-illness in rare diseases. In Rare Diseases Epidemiology: Update and Overview (pp. 283-297). Springer, Cham. https://doi.org/10.1007/978-3-319-67144-4_17
• Nadir Hastalıklar Ağı. (nd). Hakkımızda. https://www.nadirhastaliklaragi.org.tr/hakkimizda
• Numanoğlu, R. (2019). Asya Ülkelerinde Nadir Hastalıklara Yönelik Politikalar. In:Özgür İnce, Merve Deniz Pak editors. Tüm Yönleriyle Nadir Hastalıklar. Ankara: Nobel Yayıncılık, p.133-149.
• OHSAD. (nd). OHSAD 2023 Sağlık Politikaları Vizyonu. https://ohsadkurultayi.org/tr/2018-SUNUMLARI.html
• Orphanet. (2013). About rare diseases policies. https://www.orpha.net/consor/cgi-bin/Education_AboutRareDiseases.php?lng=EN&stapage=ST_EDUCATION_EDUCATION_ABOUTRAREDISEASES_POLICI
• Orphanet. (2020). Orphanet Türkiye web sayfası giriş noktası. http://www.orpha.net/national/TR-TR/index/orphanet-t%C3%BCrkiye/
• Özaltun, Ş.C., Güler, C., & Şengelen, M. (2015). Sağlık taramaları. http://www.halksagligi.hacettepe.edu.tr/diger/toplumayonelik/tarama.pdf
• Pejcic, A. V., Iskrov, G., Raycheva, R., Stefanov, R., & Jakovljevic, M. (2017). Transposition and implementation of EU rare disease policy in Eastern Europe. Expert Review of Pharmacoeconomics & Outcomes Research, 17(6), 557-566. https://doi.org/10.1080/14737167.2017.1388741
• Pogue, R. E., Cavalcanti, D. P., Shanker, S., Andrade, R. V., Aguiar, L. R., de Carvalho, J. L., & Costa, F. F. (2017). Rare genetic diseases: update on diagnosis, treatment and online resources. Drug discovery today. 23(1), 1-9. https://doi.org/10.1016/j.drudis.2017.11.002
• Princen, S. (2007). Agenda-setting in the European Union: a theoretical exploration and agenda for research. Journal of European Public Policy, 14(1), 21-38. https://doi.org/10.1080/13501760601071539
• Rodwell, C., & Aymé, S. (2015). Rare disease policies to improve care for patients in Europe. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1852(10), 2329-2335. https://doi.org/10.1016/j.bbadis.2015.02.008
• Satman, İ., Güdük, Ö., Yemenici, M., & Ertürk, N. (2019). Nadir Hastalıklar Raporu. Ankara: TÜSEB (Türkiye Halk Sağlığı ve Kronik Hastalıklar Enstitüsü).
• Shire. (2013). Rare disease impact report: Insights from patients and the medical community. California: Global Genes. https://globalgenes.org/wp-content/uploads/2013/04/ShireReport-1.pdf
• Soyer, T. (2019). Nadir Hastalıklarda Sınıflama ve Kodlama Sistemleri. In:Özgür İnce, Merve Deniz Pak editors. Tüm Yönleriyle Nadir Hastalıklar. Ankara: Nobel Akademik Yayıncılık
• T.C. Sağlık Bakanlığı - Sağlık Hizmetleri Genel Müdürlüğü. (nd). Yenidoğan Metabolik ve Endokrin Hastalık Tarama Programı (NTP). https://hsgm.saglik.gov.tr/tr/cocukergen-tp-liste/yenidogan_tarama_programi.html
• T.C. Sağlık Bakanlığı - Sağlık Hizmetleri Genel Müdürlüğü. (nd). https://hasta.saglik.gov.tr/TR-30120/uluslararasi-nadir-hastaliklar-panel-ve-calistayi.html
• TAÇESE. (2018). 2018 Yılı Birim Faaliyet Raporu. https://www.tuseb.gov.tr/tacese/uploads/genel/files/tacese-2018fr.pdf
• TAIEX. (2009). European Neighbourhood Policy And Enlargement Negotiations. https://ec.europa.eu/neighbourhood-enlargement/tenders/taiex
• TBMM. (nd). Türkiye Büyük Millet Meclisi Komisyon Tutanakları 27. Dönem. https://www.tbmm.gov.tr/develop/owa/komisyon_tutanaklari.tutanaklar?pKomKod=1049&pDonem=27
• Tengilimoğlu, D., & Güzel, A. (2020). Sağlık Politikası Belirleme Süreci ve Politikayı Belirleyen Aktörler. In Sağlık Politikası, Nobel Akademik Yayıncılık. Ankara.
• TÜHKE. (2018). 1. Bilim Kurulu Toplantı Raporu. https://www.tuseb.gov.tr/tuhke/uploads/genel/files/bilimsel_etkinlikler/birinci_bilim_kurulu_toplanti_raporu.pdf
• TÜHKE. (nd). Türkiye Halk Sağlığı ve Kronik Hastalıklar Enstitüsü (TÜHKE) Çalıştayı. https://www.tuseb.gov.tr/tuhke/uploads/genel/files/bilimsel_etkinlikler/TUHKE-Calistay-Raporu_IV-TTDK_28-29-10-2017.pdf
• Türk Nöroloji Derneği. (2019). 5th Rare Diseases Symposium and Neurogenetics Course. https://norogenetik.org
• Umumi Hıfzıssıhha Kanunu. (1930), Kanun no: 1593, Resmî Gazete Sayısı: 1489
• Walt, G., Shiffman, J., Schneider, H., Murray, S. F., Brugha, R., & Gilson, L. (2008). ‘Doing’ health policy analysis: methodological and conceptual reflections and challenges. Health policy and planning, 23(5), 308-317. https://doi.org/10.1093/heapol/czn024
• Yıldız, G., & Yalçın, S. (2020). Gazete Haberlerinin Sağlık Politikalarının Belirlenmesi ve Uygulanmasındaki Önemi: Milliyet Gazetesi MPS ve SMA Haberleri Örneği. Kurgu, 28(1), 286-304.